Immunovant Announces Closing of $200.0 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional SharesGlobeNewsWire • 09/04/20
Immunovant, Following Rival's Acquisition News, Prices Stock OfferingInvestors Business Daily • 09/02/20
Ligand OmniAb® Partner Immunovant Announced Positive Topline Results from Multicenter, Placebo-Controlled Phase 2a Trial of IMVT-1401 in Myasthenia GravisBusiness Wire • 08/25/20
Immunovant Announces Positive Topline Results from Multi-Center, Placebo-Controlled Phase 2a Trial of IMVT-1401, A Novel Investigational Anti-FcRn Antibody Delivered by Subcutaneous Injection, in Myasthenia GravisGlobeNewsWire • 08/25/20
Immunovant Reports Financial Results for the Quarter and Fiscal Year Ended March 31, 2020 and Announces Plans for Phase 3 Registrational Trial of IMVT-1401 in Myasthenia GravisGlobeNewsWire • 06/29/20
Immunovant Announces Redemption of Warrants and Achievement of First Earnout Milestone under Share Exchange AgreementGlobeNewsWire • 05/14/20
Immunovant Announces Closing of $139.4 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional SharesGlobeNewsWire • 04/16/20